Advertisement

Drug Investigation

, Volume 7, Issue 3, pp 157–160 | Cite as

Defibrotide versus Placebo in the Treatment of Intermittent Claudication

A Meta-Analysis
  • Pierantonio Ferrari
  • Giuseppina Clerici
  • Gualberto Gussoni
  • Marco Nazzari
Short Communication

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arosio E, Pancera P, Zannoni M, Arcaro G, Priante F, et al. Defibrotide and peripheral obliterative arterial disease: preliminary data. International Journal of Clinical Pharmacology Therapy and Toxicology 27: 526–529, 1989Google Scholar
  2. Avellone G, Di Garbo V, Cordova RM, Nazzari M, Bompiani G. Hemorheologic and antithrombotic effects of defibrotide in patients with claudicatio intermittens. Thrombotic and Haemorrhagic Disorders 7: 35–40, 1993Google Scholar
  3. Belfiglio A, Traietti P, Bologna E, Salvo G. Effects of oral and intravenous defibrotide on blood viscosity in patients with peripheral obliterative arterial disease. Clinical Therapeutics 11: 479–484, 1989PubMedGoogle Scholar
  4. Boissel JP, Sacks HS, Leizorovicz A, Blanchard J, Panak E, et al. Meta-analysis of clinical trials: summary of an international conference. European Journal of Clinical Pharmacology 34: 535–538, 1988PubMedCrossRefGoogle Scholar
  5. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965–1985. British Journal of Clinical Pharmacology 26: 569–576, 1988PubMedCrossRefGoogle Scholar
  6. Cappelli R, Pecchi S, Pieragalli D. et al. Effect on rheological and some peripheral haemodynamic parameters of defibrotide in POAD patients. Clinical Hemorheology 7: 247–252, 1987Google Scholar
  7. Coccheri S, Biagi G. Defibrotide. Cardiovascular Drug Reviews 9: 172–196, 1991CrossRefGoogle Scholar
  8. Cochran WG. The combination of estimates from different experiments. Biometrics 10: 101–129, 1954CrossRefGoogle Scholar
  9. Colditz GA, Halvorsen KT, Goldhaber SZ. Randomised clinical trials of transdermal nitroglycerin systems for the treatment of angina: a meta analysis. American Heart Journal 116: 174–180, 1988PubMedCrossRefGoogle Scholar
  10. Craveri A, Tomaghi G, Ranieri R, Stanzani M, Landi G, et al. Effects of defibrotide after oral and parenteral administration in patients with peripheral arterial disease (PAD). International Angiology 9: 274–277, 1990PubMedGoogle Scholar
  11. De Luca N, Crispino MR, Marcheggiani R, et al. Terapia delle arteriopatie periferiche di tipo aterosclerotico con defibrotide somministrato per os: studio controllato in doppio cieco versus placebo. Medical Praxis 8: 1–8, 1987Google Scholar
  12. Di Perri T, Laghi Pasini F, Acciavatti A, et al. Haemodynamics rheology and mechanism of action of iloprost in man. Clinical Hemorheology 10: 171–183, 1990Google Scholar
  13. Lindgaerde F, Jelnes R, Adielsson G, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 80: 1549–1556, 1989CrossRefGoogle Scholar
  14. Marelli C, Belcaro G, Girardello R. Defibrotide in patients with intermittent claudication. Improvement in blood flow, fibrinolytic activity and microcirculation after six months of treatment. Current Therapeutic Research 47: 459–465, 1990Google Scholar
  15. Marrapodi E, Leanza D, Giordano S, Nazzari M, Corsi C. Effects of defibrotide on physical performance and hemorheology picture in patients with peripheral arteriopathy. Clinical Trials and Meta-Analysis, in press, 1994Google Scholar
  16. Palmer KJ, Goa KL. Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 45: 259–294, 1993PubMedCrossRefGoogle Scholar
  17. Romeo S, Viola S, Bonaccorsi R, Iapichino G, Carullo F. II defibrotide nelle arteriopatie periferiche ostruttive. Studio policentrico. Medical Praxis 10: 141–149, 1989Google Scholar
  18. Sabba’ C, Zupo V, Dina F, Nazzari M, Albano O. A pilot evaluation of the effect of defibrotide in patients affected by peripheral arterial occlusive disease. International Journal of Clinical Pharmacology Therapy and Toxicology 26: 249–252, 1988Google Scholar
  19. Strano A, Fareed J, Sabba’ C, et al. A double blind, multicenter, placebo controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease. Seminars in Thrombosis and Hemostasis 17(Suppl. 2): 228–234, 1991PubMedGoogle Scholar
  20. Ulutin ON. Clinical effectiveness of defibrotide in vasoocclusive disorders and its mode of actions. Seminars in Thrombosis and Hemostasis 14 (Suppl.): 58–63, 1988PubMedGoogle Scholar
  21. Vogt MT, Wolfson SK, Kuller LH. Lower extremity arterial disease and the aging process: a review. Journal of Clinical Epidemiology 45: 529–542, 1992PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Pierantonio Ferrari
    • 1
  • Giuseppina Clerici
    • 1
  • Gualberto Gussoni
    • 1
  • Marco Nazzari
    • 1
  1. 1.Medical DepartmentCrinos SpAVilla GuardiaItaly

Personalised recommendations